All In Biotech

Drug Trial Radar · NCT07716098

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Jul 23, 2026

Primary completion

Dec 27, 2028

Study completion Sep 12, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \[MDD\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

  • Esketamine 56 mgDrug

    Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.

  • Esketamine 84 mgDrug

    Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.

  • PlaceboDrug

    Participants will self-administer placebo as intranasal spray into each nostril.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-Blind (DB) Treatment Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 to the End of the 4-Week Double-Blind Treatment PhaseTime frame: Baseline (Day 1 [prerandomization]) up to end of the 4-Week DB treatment phase (Day 28)

Locations

39 sites in 4 countries. Site status is shown where the registry gives one.

  • Anderson Clinical Research

    Redlands, California · Recruiting

  • Artemis Institute for Clinical Research

    San Diego, California · Recruiting

  • University of Connecticut Health Center

    Farmington, Connecticut · Recruiting

  • American Family Research Group

    Cape Coral, Florida · Recruiting

  • Pharmax Research Clinic Inc

    Miami, Florida · Recruiting

  • Charter Research Orlando

    Orlando, Florida · Recruiting

  • Psych Atlanta, P.C.

    Marietta, Georgia · Recruiting

  • Accelerated Clinical Research Group LLC

    Snellville, Georgia · Recruiting

  • Midwest Research Group

    Saint Maries, Idaho · Recruiting

  • Psychiatric Medicine Associates LLC

    Skokie, Illinois · Recruiting

  • Adams Clinical Watertown

    Watertown, Massachusetts · Recruiting

  • Neurobehavioral Research Inc

    Cedarhurst, New York · Recruiting

  • The Medical Research Network, LLC

    New York, New York · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Northwest Clinical Research Center

    Bellevue, Washington · Recruiting

  • Beijing Anding Hospital of Capital Medical University

    Beijing, China · Recruiting

  • Beijing Huilongguan Hospital

    Beijing, China · Recruiting

  • Wuhu Hospital of Beijing Anding hospital

    Wuhu, China · Recruiting

  • Heart Care Clinic Omachi

    Akita, Japan · Recruiting

  • Rainbow & Sea Hospital

    Karatsu, Japan · Recruiting

  • Kishiro Mental Clinic

    Kawasaki, Japan · Recruiting

  • Tatsuta Clinic

    Kobe, Japan · Recruiting

  • National Center of Neurology and Psychiatry

    Kodaira, Japan · Recruiting

  • Juntendo University Koshigaya Hospital

    Koshigaya, Japan · Recruiting

  • Ichikawa Clinic

    Maebashi, Japan · Recruiting

  • The Jikei University Hospital

    Minatoku, Japan · Recruiting

  • Kyorin University Hospital

    Mitaka, Japan · Recruiting

  • Miyakonojo Shinsei Hospital

    Miyakonojō, Japan · Recruiting

  • Arata Clinic

    Nagasaki, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Japan · Recruiting

  • Sangenjaya neurology-psychosomatic clinic

    Setagaya-ku/Tokyo, Japan · Recruiting

  • Maynds Tower Mental Clinic

    Shibuya Tokyo, Japan · Recruiting

  • Tottori University Hospital

    Tottori, Japan · Recruiting

  • Kaohsiung Medical University Chung Ho Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Chung Shan Medical University Hospital

    Taichung, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Taipei Medical University

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.